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A B S T R A C T
The aim of our study was to assess whether the influence of nutritional support, consisting of counseling, enteral liq-
uids support and pharmacologic support, can slow down weight loss and whether the change in weight has the impact
on the performance status in our patients. In our study 44 patients with pancreatic cancer were included – 26 males
(mean age 69 years  2.4 years) and 18 females (mean age 63  3.2 years). Metastatic disease was found in 21 patients, 15
patients had liver metastasis. Locally advanced disease was found in 24 patients and metastatic and locally advanced
disease in 17 patients. Surgery was performed in 34 patients. Forty four (100%) patients underwent nutritional counsel-
ing, 33 of them (75%) took supplemental enteral feeding and 44 (100%) took megestrol acetate 400 mg per a day. The pa-
tients were followed up during 8 weeks during 5 visits. At first visit we took initial nutritional status of patients. Appetite
loss, weight gain and Karnofsky performance status were monitored at every visit. All patients were treated with gemci-
tabin for a 7 week period. Results: NTS score at initial visit in 44 patients (100%) was  5. Using nutritional counseling,
enteral food substitution and pharmacological support, weight gain was observed in 61.1% patients and appetite im-
proved. Average KPS mostly improved after first month of therapy while after two months was again at the basal level.
With nutritional counseling, supplemental feeding and pharmacologic support weight loss in our patients slowed down
and appetite improved. Despite of that, Karnofsky Performance Status didn’t change significantly, reflecting the impact
of the disease itself and chemotherapy procedures to the patient’s condition. We can conclude that nutritional and phar-
macological support can temporarily stop weight loss and improve appetite, social life and quality of life in those groups
of patients but have no implications on patients KPS and course of their disease.
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Introduction
Approximately 200 000 patients die of pancreatic can-
cer worldwide annually. Pancreatic cancer represents the
fourth leading cause of cancer-related mortality. Despite
of intensive research, etiology of pancreatic carcinoma
remains largely unknown but risk factors thought to be
associated with pancreatic cancer include smoking,
chronic pancreatitis and hereditary cancer (1,2). It is
usually diagnosed late; more than 80% of patients have
macroscopic disseminated disease at the time of diagno-
sis. Curative surgery requires specialized expertise found
in limited centers in which resection rate is still under
50%. The tumor shows high level of resistance to all can-
cer treatment modalities1,2.
Pancreatic cancer has the highest incidence of cache-
xia compared to other tumor entities (more than 80% of
cases)3. Tumor growth is associated with profound meta-
bolic and neurochemical alterations that lead to the on-
set of anorexia-cachexia syndrome. This syndrome has a
large impact on morbidity, mortality and patient’s Qual-
ity of Life3,4.
The process appears to be mediated by circulating cat-
abolic factors, either secreted by the tumor alone or in as-
sociation with host-derived factors such as tumor necro-
sis factor a (TNFa), interleukins (IL-1, IL-6), interferon
g (INFg), leukemia inhibitory factor (LIF), proteolysis-in-
ducing factor (PIF) and lipid mobilizing factor (LMF)3–5.
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